Discussion in 'COVID-19' started by Obliged Friend, Jul 18, 2021.
Remdesivir makes it worse.
Conclusions and Relevance In this cohort study of US veterans hospitalized with COVID-19, remdesivir treatment was not associated with improved survival but was associated with longer hospital stays. Routine use of remdesivir may be associated with increased use of hospital beds while not being associated with improvements in survival.
I can never understand the "thinking" behind these single drug test protocols? A single drug by itself is almost never an effective solution. If you go see your doctor and are diagnosed with a heart problem, or kidney problem, or liver problem; do you think you are going to get a prescription for one single drug? You will get a prescription for probably at least 4 or 5 drugs that need to be taken together. Rendesivir (or HCQ, or Ivermectin) have all shown to be able to be part of an effective treatment protocol. But, in order to work effectively they need to be combined with azithromycin, a blood thinner, and high doses of C, D, and zinc; and the treatment needs to be started early, like within the first week of a positive test. If delayed until the patient is already in the hospital and seriously sick and needing oxygen, the results are much less positive. If started early, the results are almost 100% effective at preventing the need for hospitalization.
I recall reading an article about Israeli scientists working on a treatment using a 3 drug cocktail showing 100% effective against all variants of covid. Must be having a senior moment - can't find the story now.....I think it was on WIONnews.
Not read about that, but (from https://www.israel21c.org/has-israel-just-found-the-cure-for-covid/): Not sure of the reliability of the source and this was published 5 months ago)
EXO-CD24, an experimental inhaled medication developed at Tel Aviv Sourasky Medical Center, cured all 30 moderate-to-severe cases in a Phase I clinical trial. Developed over the past six months at the hospital, EXOCD24 stops the “cytokine storm” – where the immune system goes out of control and starts attacking healthy cells – that occurs in the lungs of 5-7% of Covid-19 patients. “To date, the preparation has been tried with great success on 30 severe patients, in 29 of whom the medical condition improved within two to three days and most of them were discharged home within three to five days. The 30th patient also recovered but after a longer time,” the hospital reports.
........... “The preparation is given by inhalation, once a day, for only a few minutes, for five days,” Shapira said.
She said the experimental treatment has two unique characteristics. The first is that it inhibits the over-secretion of cytokines. The second is that it is delivered directly to the lungs and therefore has no systemic side effects that injected or oral drugs can cause.
.......... Arber added that this advanced preparation “can be produced quickly and efficiently and at a very low cost in every pharmaceutical facility in the country, and in a short time globally.”
Prof. Ronni Gamzu, CEO of the medical center, said, “Prof. Arber’s results for first-phase research were excellent and gave us all confidence in the method he has been researching [here] for many years. I personally assisted him in further obtaining the approvals from the Ministry of Health for further research.”
Meanwhile, Enlivex Therapeutics last week reported positive results from a multi-center Phase II clinical trial of its experimental Covid-19 immunotherapy drug Allocetra in severe and critical Covid-19 patients. Nine severe and seven critical Covid-19 patients were treated with Allocetra in the Phase II clinical trial. Fourteen of them recovered and were discharged from the hospital after an average of 5.3 days. Altogether, 19 out of 21 Phase II and Phase Ib Allocetra trial patients recovered and were discharged from the hospital after an average of 5.6 days. Most of the patients in both studies had pre-existing risk factors such as male gender, obesity and hypertension.
“The results we have seen from the 12 Covid-19 patients treated to date with Allocetra are exciting,” said Prof. Vernon van Heerden, head of the General Intensive Care Unit at Hadassah and the lead investigator of both clinical trials. “The Phase II patients who have been discharged from the hospital are currently healthy. We believe that these compelling results have demonstrated the safety and efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex’s product candidate to benefit severe and critical Covid-19 patients as well as others suffering from cytokine storms and organ dysfunctions across various clinical indications.”
Mevorach said Allocetra “may have utility as a safe and efficacious treatment … regardless of the specific coronavirus mutation that afflicted the patients, and across different life-threatening, high mortality clinical indications with high unmet medical needs.”